Scholarlink

Background <p>Molecular imaging of adrenal tumors has become established in clinical routine, because they often cannot be characterized using morphological imaging alone. It can provide an important contribution to the localization and characterization of these lesions.</p> Objectives <p>The use of various radiopharmaceuticals forms the basis of molecular imaging via positron emission tomography (PET)/computed tomography (CT) and single photon emission computed tomography (SPECT)/CT.</p> Materials and methods <p>We conducted a&#xa0;literature search on established and novel PET- and SPECT-tracers used in adrenocortical tumors, pheochromocytomas, and paragangliomas.</p> Results <p>For distinguishing adrenocortical carcinomas from adenomas imaging of glucose metabolism using [<sup>18</sup>F]FDG-PET/CT (FDG: fluorodeoxyglucose) is helpful. CXC&#xa0;chemokine receptor type&#xa0;4 (CXCR4)-targeting radioligands like [<sup>68</sup>Ga]Ga-PentixaFor show good sensitivity for detection in primary hyperaldosteronism and are subject to clinical trials. In various studies, [<sup>11</sup>C]metomidate PET/CT demonstrated high specificity and high sensitivity in the identification of unilateral aldosterone-producing adenomas in patients compared to invasive adrenal vein catheterization (AVS) and can be used as an alternative. PentixaFor PET/CT also demonstrated high sensitivity and specificity for the diagnosis of cortisol-producing adenomas in studies. Molecular imaging of pheochromocytomas and paragangliomas utilizes the uptake of catecholamine analogues or metabolites, [18F]F-DOPA, or somatostatin receptor expression.</p> Conclusion <p>Molecular imaging can make an essential contribution to the noninvasive diagnosis of adrenal tumors, pheochromocytomas, and paragangliomas by visualizing various metabolic processes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neue bildgebende Verfahren zur Differenzialdiagnose von Nebennierentumoren, Phäochromozytomen und Paragangliomen

  • 期刊论文

  • 发表日期：

    2026年1月29日

查看全文
  • Friederike Eilsberger,
  • Kerstin Michalski,
  • Markus Luster

摘要

Background

Molecular imaging of adrenal tumors has become established in clinical routine, because they often cannot be characterized using morphological imaging alone. It can provide an important contribution to the localization and characterization of these lesions.

Objectives

The use of various radiopharmaceuticals forms the basis of molecular imaging via positron emission tomography (PET)/computed tomography (CT) and single photon emission computed tomography (SPECT)/CT.

Materials and methods

We conducted a literature search on established and novel PET- and SPECT-tracers used in adrenocortical tumors, pheochromocytomas, and paragangliomas.

Results

For distinguishing adrenocortical carcinomas from adenomas imaging of glucose metabolism using [18F]FDG-PET/CT (FDG: fluorodeoxyglucose) is helpful. CXC chemokine receptor type 4 (CXCR4)-targeting radioligands like [68Ga]Ga-PentixaFor show good sensitivity for detection in primary hyperaldosteronism and are subject to clinical trials. In various studies, [11C]metomidate PET/CT demonstrated high specificity and high sensitivity in the identification of unilateral aldosterone-producing adenomas in patients compared to invasive adrenal vein catheterization (AVS) and can be used as an alternative. PentixaFor PET/CT also demonstrated high sensitivity and specificity for the diagnosis of cortisol-producing adenomas in studies. Molecular imaging of pheochromocytomas and paragangliomas utilizes the uptake of catecholamine analogues or metabolites, [18F]F-DOPA, or somatostatin receptor expression.

Conclusion

Molecular imaging can make an essential contribution to the noninvasive diagnosis of adrenal tumors, pheochromocytomas, and paragangliomas by visualizing various metabolic processes.